The drugs included in the warning are Pfizer’s Ibrance, Novartis’ Kisqali, and Eli Lilly’s Verzenio.
Though cases are rare, the FDA said the drugs could cause interstitial lung disease and pneumonitis.
The FDA warned patients taking the breast cancer drugs to watch for symptoms of pulmonary distress, including difficulty breathing and shortness of breath. Physicians should regularly monitor patients taking the drugs for symptoms of ILD and pneumonitis.
Patients who have developed ILD or pneumonitis should permanently stop taking the breast cancer drugs, the FDA said.
However, the FDA said the overall benefits of the breast cancer drugs are greater than the risks.
Read the full report here.
More articles on pharmacy:
Purdue Pharma files for bankruptcy
DEA proposes to cut opioid production in half
Pharmacist-led HIV prevention treatment program could boost patient satisfaction, study finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
